Search Results - mesothelin

10 Results

Sort By:

Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers

Abstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan

Keywords(s): ANTIBODY, Immunotherapy, MESOTHELIN, therapeutic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy

Abstract: Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived...

Published: 4/8/2024 | Inventor(s): Steven Feldman, Steven Rosenberg, Ira Pastan

Keywords(s): CAR, Immunotherapy, MESOTHELIN, T-CELLS

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents

Abstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Masanori Onda, Tapan Bera, Mitchell Ho

Keywords(s): ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin

Abstract: Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer. Researchers at the National Cancer Institute’s...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan, Jessica Hong, Nan Li

Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, HO, MESOTHELIN, Mesothelioma, Recombinant Immunotoxins, RITs

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics

Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent

Abstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Xiu Fen Liu, Tapan Bera, Masanori Onda, Mitchell Ho

Keywords(s): ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer

Abstract: The National Cancer Institute seeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitro Mesothelin is...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan, Dimiter Dimitrov, Zhewei Tang, Mingqian Feng, Wei Gao

Keywords(s): Epitopes, MESOTHELIN, Monoclonal Antibodies

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment

Abstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers, such as malignant mesothelioma, ovarian cancer and pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. Because of this selective expression, mesothelin is an excellent candidate for targeted therapeutics,...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Ira Pastan, Yen Phung, Yifan Zhang, Raffit Hassan, Wei Gao

Keywords(s): Epitope, MESOTHELIN

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Nan Li, Dan Li

Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity

Abstract: Recombinant Immunotoxins (RITs) are chimeric molecules composed of an antigen binding domain and toxin. The antigen binding domain component targets the cancer cell and delivers the toxin component to the cell. However, the efficacy of RITs is limited by their short half-life once they are in the patient. To address this problem, investigators...

Published: 5/21/2024 | Inventor(s): Ira Pastan, Zeliang Zheng

Keywords(s): Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, Recombinant Immunotoxins, RITs

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice

Abstract: Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models. Investigators...

Published: 5/21/2024 | Inventor(s): Christine Alewine, Serguei Kozlov, Xianyu Zhang, Theresa Guerin, Theresa O'Sullivan, Norman Collins, Jerome Schlomer

Keywords(s): Alewine, Bl6/TPO, Cancer Animal Model, hMSLN, Humanized Mice, MESOTHELIN, MSLN, Murine Model, THYROID

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Oncology